Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
Next revision
Previous revision
home:diseases:celiac [03.13.2019]
sallieq [recent research]
home:diseases:celiac [07.13.2019] (current)
sallieq [recent research]
Line 66: Line 66:
 Findings suggest that neither olmesartan nor other ARBs were associated with diarrhea among patients undergoing endoscopy. The spruelike enteropathy recently associated with olmesartan is likely a rare adverse effect and milder presentations are unlikely. ​ (({{pubmed>​long:​25023670}})) Findings suggest that neither olmesartan nor other ARBs were associated with diarrhea among patients undergoing endoscopy. The spruelike enteropathy recently associated with olmesartan is likely a rare adverse effect and milder presentations are unlikely. ​ (({{pubmed>​long:​25023670}}))
  
-In a methotrexate-induced model of intestinal mucositisolmesartan reduced inflammation ​and induced enteropathy characterized by severe diarrheaweight loss, and reduced sucrose activity  ​(({{pubmed>​long:​25947920}}))+In 2015 I read that 6 individuals in the USA are currently suing maker of Benicar. Somewhere I saw that 1.9 million individuals are currently taking Olmesartan Medoxomil. ​ 6 in 1.9 million ? Seems pretty rare to me. (Editor) 
 + 
 +2018 data show that OLM is an Nrf2 activatorNFkB inhibitor ​and apoptosis inhibitor in an experimental model of ulcerative colitis. Overallthe study indicates that OLM shows promise as a potential therapy for the treatment of human inflammatory bowel diseases 
 +(({{pubmed>​long:​30594690}}))
  
 {{tag>​diseases }} {{tag>​diseases }}
home/diseases/celiac.1552512702.txt.gz · Last modified: 03.13.2019 by sallieq
© 2015, Autoimmunity Research Foundation. All Rights Reserved.